Bepreve (Bepotastine 1.5%)

Approved uses

Ocular itching in allergic conjunctivitis

1 drop in the affected eye(s) BID

Itch relief begins within 3 minutes and persists at least 8 hours after a single drop.

OFF-LABELNot in the FDA label for this product

Vernal keratoconjunctivitis

1 drop BID, the labeled regimen, continued for 8 weeks in the cited trial

Comparative · n=50 · not sig

Single center open label comparative trial in 50 patients with vernal keratoconjunctivitis, aged 5 to 15, allocated to 1.5% solution or olopatadine 0.1% BID for 8 weeks. The authors report quicker relief of watering, ocular discomfort, and conjunctival hyperemia in the bepotastine arm but state the difference was not statistically significant; olopatadine improved papillary hypertrophy faster, and the two were equal for itching.

Sruthi V, Reddy RN, Sowmini K, Grace NS. To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital. Indian J Pharmacol. 2020;52(6):476-481. Described by its authors as a randomized, open-label, comparative study; PubMed indexes it as a journal article, not a randomized controlled trial.

Contraindications

History of hypersensitivity reactions to bepotastine or any other ingredient in the formulation.